NCT00022360View on ClinicalTrials.gov

Taurolidine in Treating Patients With Recurrent or Progressive Glioma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2001

Primary Completion Date

October 31, 2001

Study Completion Date

October 31, 2001

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

taurolidine

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00022360 - Taurolidine in Treating Patients With Recurrent or Progressive Glioma | Biotech Hunter | Biotech Hunter